Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Fletcher

Showing results (111-120 of 205) with videos related to

Pageof 21
Sort By:
Molecular Cancer Therapeutics|April 9, 2015
CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma ProtuberansGrant Eilers, Jeffrey T Czaplinski, Mark Mayeda, et al.
Nature|October 8, 2010
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumoursPing Chi, Yu Chen, Lei Zhang, et al.
Oncogene|March 1, 2005
Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genesAndre M Oliveira, Antonio R Perez-Atayde, Paola Dal Cin, et al.
Current Protocols in Human Genetics|October 5, 2010
Reporting of diagnostic cytogenetic resultsAzra H Ligon, Cynthia C Morton, Frederick R Bieber, et al.
BMC Cancer|July 16, 2016
No preclinical rationale for IGF1R directed therapy in chondrosarcoma of boneElisabeth F P Peterse, Arjen H G Cleven, Yvonne De Jong, et al.
Current Protocols in Human Genetics|July 8, 2011
Reporting of diagnostic cytogenetic resultsAzra H Ligon, Cynthia C Morton, Frederick R Bieber, et al.
The American Journal of Pathology|April 28, 2004
Activation of the GLI oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic neoplasms: pericytoma with t(7;12)Anna Dahlén, Christopher D M Fletcher, Fredrik Mertens, et al.
The Journal of Pathology|May 19, 2009
c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programmeEric L Snyder, Deborah J Sandstrom, Kenneth Law, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatmentEvangelia Razis, Panayotis Selviaridis, Stephanos Labropoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT DysregulationCésar Serrano, Yuexiang Wang, Adrián Mariño-Enríquez, et al.
Pageof 21

Showing results (111-120 of 205) with videos related to

Sort By:
Pageof 21
Molecular Cancer Therapeutics|April 9, 2015
CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma ProtuberansGrant Eilers, Jeffrey T Czaplinski, Mark Mayeda, et al.
Nature|October 8, 2010
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumoursPing Chi, Yu Chen, Lei Zhang, et al.
Oncogene|March 1, 2005
Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genesAndre M Oliveira, Antonio R Perez-Atayde, Paola Dal Cin, et al.
Current Protocols in Human Genetics|October 5, 2010
Reporting of diagnostic cytogenetic resultsAzra H Ligon, Cynthia C Morton, Frederick R Bieber, et al.
BMC Cancer|July 16, 2016
No preclinical rationale for IGF1R directed therapy in chondrosarcoma of boneElisabeth F P Peterse, Arjen H G Cleven, Yvonne De Jong, et al.
Current Protocols in Human Genetics|July 8, 2011
Reporting of diagnostic cytogenetic resultsAzra H Ligon, Cynthia C Morton, Frederick R Bieber, et al.
The American Journal of Pathology|April 28, 2004
Activation of the GLI oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic neoplasms: pericytoma with t(7;12)Anna Dahlén, Christopher D M Fletcher, Fredrik Mertens, et al.
The Journal of Pathology|May 19, 2009
c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programmeEric L Snyder, Deborah J Sandstrom, Kenneth Law, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatmentEvangelia Razis, Panayotis Selviaridis, Stephanos Labropoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT DysregulationCésar Serrano, Yuexiang Wang, Adrián Mariño-Enríquez, et al.
Pageof 21